Clinical trial

Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

NCT03947216

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2020-10-23

PhasePHASE2

Study timeline

Study start (actual)2020-10-23Date precision: day

Registry last updated2026-03-16

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Parkinson Diseaseunresolved

Interventions

Active drug: pimavanserin 17mg (2 strength tablets)DRUG

Placebo: 2 tablets containing same excipients except active compoundDRUG

Assessment of severity of ICD (impulse control disorders)BEHAVIORAL

Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviorsBEHAVIORAL

Assessment of quality of lifeBEHAVIORAL

Assessment of depressionBEHAVIORAL

Assessment of cognitionBEHAVIORAL

Assessment of severity of Parkinson DiseaseBEHAVIORAL

Blood analysisPROCEDURE

Cardiac monitoringPROCEDURE

Sponsors & collaborators

University Hospital, Strasbourg, Francelead sponsor

NS-PARK Networkcollaborator

EUCLID Clinical Trial Platformcollaborator

F-CRINcollaborator

ACADIA Pharmaceuticals Inc.collaborator

Mapped research locations

ParisFrance1 ToulouseFrance1 MarseilleFrance1 StrasbourgFrance1 LilleFrance1 NantesFrance1 RennesFrance1 Clermont-FerrandFrance1 GrenobleFrance1 RouenFrance1 BesançonFrance1 CréteilFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03947216 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.